Matt Hewitt
Stock Analyst at Craig-Hallum
(3.96)
# 527
Out of 4,784 analysts
42
Total ratings
58.33%
Success rate
9.46%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $9.11 | +31.72% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $3.59 | +67.13% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $25.96 | +23.27% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $35.01 | +82.80% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $107.62 | +30.09% | 3 | Jul 9, 2024 | |
| SLP Simulations Plus | Reiterates: Buy | $56 | $24.29 | +130.55% | 7 | Jul 3, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $2.15 | +365.12% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $19.96 | +50.30% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $2.73 | +156.41% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $133.41 | +49.91% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.42 | +313.22% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $8.09 | +270.83% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.15 | +34,682.61% | 1 | Jan 4, 2022 |
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $9.11
Upside: +31.72%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $3.59
Upside: +67.13%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $25.96
Upside: +23.27%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $35.01
Upside: +82.80%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $107.62
Upside: +30.09%
Simulations Plus
Jul 3, 2024
Reiterates: Buy
Price Target: $56
Current: $24.29
Upside: +130.55%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $2.15
Upside: +365.12%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $19.96
Upside: +50.30%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $2.73
Upside: +156.41%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $133.41
Upside: +49.91%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $2.42
Upside: +313.22%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $8.09
Upside: +270.83%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.15
Upside: +34,682.61%